Articles

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in pat...

Authors: Jian Hou, Jie Jin, Yan Xu, Depei Wu, Xiaoyan Ke, Daobin Zhou, Jin Lu, Xin Du, Xiequn Chen, Junmin Li, Jing Liu, Neeraj Gupta, Michael J. Hanley, Hongmei Li, Zhaowei Hua, Bingxia Wang…

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1...

Authors: Si-Yang Liu and Yi-Long Wu

Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia

Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (G-PBSC) has largely replaced unstimulated bone marrow (un-BM) for allografting because of accelerated engraftment, but with ...

Authors: Qian Fan, Hui Liu, Xinquan Liang, Ting Yang, Zhiping Fan, Fen Huang, Yiwen Ling, Xin Liao, Li Xuan, Na Xu, Xiaojun Xu, Jieyu Ye and Qifa Liu

Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who r...

Authors: Ying-Jun Chang, Yu Wang, Yan-Rong Liu, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Kai-Yan Liu and Xiao-Jun Huang

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

The two murine double minute (MDM) family members MDM2 and MDMX are at the center of an intense clinical assessment as molecular target for the management of cancer. Indeed, the two proteins act as regulators ...

Authors: Veronica Tisato, Rebecca Voltan, Arianna Gonelli, Paola Secchiero and Giorgio Zauli

The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis

UBE2O is proposed as a ubiquitin-conjugating enzyme, but its function was largely unknown.

Authors: Yujia Xu, Zubin Zhang, Jie Li, Jiefei Tong, Biyin Cao, Paul Taylor, Xiaowen Tang, Depei Wu, Michael F. Moran, Yuanying Zeng and Xinliang Mao

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and re...

Authors: Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne-Rauzy, Moshe Mittelman, Petra Muus, Stephen D. Nimer, Eva Hellström-Lindberg, Bayard L. Powell, Agnes Guerci-Bresler, Mikkael A. Sekeres, H. Joachim Deeg, Consuelo del Cañizo, Peter L. Greenberg, Jamile M. Shammo, Barry Skikne…

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal prognosis. Allogeneic stem cell transplantation (HSCT) in active disease is an alternative therapeutic strategy. The increased av...

Authors: Eolia Brissot, Myriam Labopin, Matthias Stelljes, Gerhard Ehninger, Rainer Schwerdtfeger, Jürgen Finke, Hans-Jochem Kolb, Arnold Ganser, Kerstin Schäfer-Eckart, Axel R. Zander, Donald Bunjes, Stephan Mielke, Wolfgang A. Bethge, Noël Milpied, Peter Kalhs, Igor-Woflgang Blau…

A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients

Protein tyrosine phosphatase receptor gamma (PTPRG) is a ubiquitously expressed member of the protein tyrosine phosphatase family known to act as a tumor suppressor gene in many different neoplasms with mechan...

Authors: Marzia Vezzalini, Andrea Mafficini, Luisa Tomasello, Erika Lorenzetto, Elisabetta Moratti, Zeno Fiorini, Tessa L. Holyoake, Francesca Pellicano, Mauro Krampera, Cristina Tecchio, Mohamed Yassin, Nader Al-Dewik, Mohamed A. Ismail, Ali Al Sayab, Maria Monne and Claudio Sorio

Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT

The feasibility of cord blood transplantation (CBT) in adults is limited by the relatively low number of hematopoietic stem/progenitor cells contained in one single CB unit. The infusion of two CB units from d...

Authors: Frédéric Baron, Annalisa Ruggeri, Eric Beohou, Myriam Labopin, Mohamad Mohty, Didier Blaise, Jan J Cornelissen, Patrice Chevallier, Guillermo Sanz, Eefke Petersen, Bipin N Savani, Eliane Gluckman and Arnon Nagler

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a novel therapeutic ag...

Authors: Ana-Alicia López-Iglesias, Ana B. Herrero, Marta Chesi, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Irena Misiewicz-Krzeminska, Dalia Quwaider, Montserrat Martín-Sánchez, Daniel Primo, Teresa Paíno, P. Leif Bergsagel, Thomas Mehrling, Marcos González-Díaz, Jesús F. San-Miguel, María-Victoria Mateos…

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes

C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients...

Authors: Michela Sica, Tommaso Rondelli, Patrizia Ricci, Maria De Angioletti, Antonio M. Risitano and Rosario Notaro

MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway

Brain metastasis (BM) is associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). Recent studies demonstrated that microRNA-330-3p (miR-330-3p) was involved in NSCLC brain metastasis...

Authors: Chun-Hua Wei, Gang Wu, Qian Cai, Xi-Can Gao, Fan Tong, Rui Zhou, Rui-Guang Zhang, Ji-Hua Dong, Yu Hu and Xiao-Rong Dong

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia

T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) and programmed cell death protein 1 (PD-1) are important inhibitory receptors that associate with T cell exhaustio...

Authors: Liuluan Zhu, Yaxian Kong, Jianhong Zhang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Neil D. Palmisiano, Ming Wang, Bei Jia, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hui Zeng and Hong Zheng

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

MDM2 and CDK4 are frequently co-amplified in well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS). We aimed to determine whether combined MDM2/CDK4 targeting is associated wi...

Authors: Audrey Laroche-Clary, Vanessa Chaire, Marie-Paule Algeo, Marie-Alix Derieppe, François L. Loarer and Antoine Italiano

Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases

Lymphatic metastasis is one of the leading causes of death in patients with different types of cancer and is the main prognostic factor for the disease survival. The formation of new lymphatic vessels (lymphan...

Authors: Melissa García-Caballero, Jenny Paupert, Silvia Blacher, Maureen Van de Velde, Ana Rodríguez Quesada, Miguel Angel Medina and Agnès Noël

Role of epigenetics-microRNA axis in drug resistance of multiple myeloma

Despite administration of novel therapies, multiple myeloma (MM) remains incurable with resistance to drugs leading to relapse in most patients. Thus, it is critical to understand the detailed mechanisms under...

Authors: Nasrin Rastgoo, Jahangir Abdi, Jian Hou and Hong Chang

Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation

Impaired T cell reconstitution remains a major deterrent in the field of bone marrow (BM) transplantation (BMT) due to pre-conditioning-induced damages inflicted to the thymi of recipient hosts. Given the prev...

Authors: Aurélie Tormo, Fatemeh Khodayarian, Yun Cui, Edouard Al-Chami, Reem Kanjarawi, Beatriz Noé, Huijie Wang and Moutih Rafei

Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing

Sickle cell disease (SCD) is a disorder of red blood cells (RBCs) expressing abnormal hemoglobin-S (HbS) due to genetic inheritance of homologous HbS gene. However, people with the sickle cell trait (SCT) carr...

Authors: Jianguo Wen, Wenjing Tao, Suyang Hao and Youli Zu

Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity

Abnormalities of tubulin polymerization and microtubule assembly are often seen in cancer, which make them very suitable targets for the development of therapeutic approach against rapidly dividing and aggress...

Authors: Yong Teng, Yafei Cai, Wenhu Pi, Lixia Gao and Chloe Shay

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

In B cell non-Hodgkin lymphoma (B-NHL), rituximab-containing reduced-intensity conditioning regimens (R-RIC) have been shown to provide favorable outcomes in single-arm studies; however, large multicenter stud...

Authors: Narendranath Epperla, Kwang Woo Ahn, Sairah Ahmed, Madan Jagasia, Alyssa DiGilio, Steven M. Devine, Samantha Jaglowski, Vanessa Kennedy, Andrew R. Rezvani, Sonali M. Smith, Anna Sureda, Timothy S. Fenske, Mohamed A. Kharfan-Dabaja, Phillipe Armand and Mehdi Hamadani

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells

Patients with B cell lymphomas bearing MYC translocation combined with translocation involving other genes, such as BCL2, BCL3, or BCL6, defined as double-hit lymphoma (DHL), have a poor prognosis. Recent studies...

Authors: Keichiro Mihara, Tetsumi Yoshida, Yoshifumi Takei, Naomi Sasaki, Yoshihiro Takihara, Junya Kuroda and Tatsuo Ichinohe

SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B

SIX homeobox 3 (SIX3) is a member of the sine oculis homeobox transcription factor family. It plays a vital role in the nervous system development. Our previous study showed that the SIX3 gene is hypermethylat...

Authors: Zhibin Yu, Yingnan Sun, Xiaoling She, Zeyou Wang, Shuai Chen, Zhiyong Deng, Yan Zhang, Qiang Liu, Qing Liu, Chunhua Zhao, Peiyao Li, Changhong Liu, Jianbo Feng, Haijuan Fu, Guiyuan Li and Minghua Wu

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

Distant metastasis of triple-negative breast cancer (TNBC) to other organs, e.g., the lungs, has been correlated with poor survival rates among breast cancer patients. Therefore, the identification of useful t...

Authors: Shang-Pen Huang, Pei-Yao Liu, Chih-Jung Kuo, Chi-Long Chen, Wei-Jiunn Lee, Yu-Hui Tsai and Yuan-Feng Lin

Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

Allogenic hematopoietic stem cell transplantation (allo-SCT) is the most effective post-remission treatment for adults with high-risk acute lymphoblastic leukemia (ALL). The aim of the study was to analyze res...

Authors: Nicole Santoro, Annalisa Ruggeri, Myriam Labopin, Andrea Bacigalupo, Fabio Ciceri, Zafer Gülbaş, He Huang, Boris Afanasyev, William Arcese, Depei Wu, Yener Koc, Johanna Tischer, Stella Santarone, Sebastian Giebel, Mohamad Mohty and Arnon Nagler

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

The CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including...

Authors: Manoj K. Kashyap, Carlos I. Amaya-Chanaga, Deepak Kumar, Brett Simmons, Nanni Huser, Yin Gu, Max Hallin, Kevin Lindquist, Rolla Yafawi, Michael Y. Choi, Ale-Ali Amine, Laura Z. Rassenti, Cathy Zhang, Shu-Hui Liu, Tod Smeal, Valeria R. Fantin…

The chimeric monoclonal antibody MHCSZ-123 against human von Willebrand factor A3 domain inhibits high-shear arterial thrombosis in a Rhesus monkey model

SZ-123, a murine monoclonal antibody that targets the human von Willebrand factor (VWF) A3 domain and blocks the binding of collagen, is a powerful antithrombotic. In a Rhesus monkey model of thrombosis, SZ-12...

Authors: Shundong Ji, Miao Jiang, Bin Yan, Fei Shen, Yang He, Aini Wan, Lijun Xia, Changgeng Ruan and Yiming Zhao

Clinical applications of PD-L1 bioassays for cancer immunotherapy

Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expressio...

Authors: Delong Liu, Shuhang Wang and Wendy Bindeman

Intrathymic injection of hematopoietic progenitor cells establishes functional T cell development in a mouse model of severe combined immunodeficiency

Even though hematopoietic stem cell transplantation can be curative in patients with severe combined immunodeficiency, there is a need for additional strategies boosting T cell immunity in individuals sufferin...

Authors: Andrea Z. Tuckett, Raymond H. Thornton, Richard J. O’Reilly, Marcel R. M. van den Brink and Johannes L. Zakrzewski

Incorporation of high-dose ¹³¹I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study

In our previous SMC NB-2004 study of patients with high-risk neuroblastomas, which incorporated total-body irradiation (TBI) with second high-dose chemotherapy and autologous stem cell transplantation (HDCT/au...

Authors: Ji Won Lee, Sanghoon Lee, Hee Won Cho, Youngeun Ma, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Eun Joo Cho, Suk-Koo Lee and Do Hoon Lim

An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets

A microRNA (miRNA) collection on the imprinted 14q32 MEG3 region has been associated with outcome in osteosarcoma. We assessed the clinical utility of this miRNA set and their association with methylation status.

Authors: Katherine E. Hill, Andrew D. Kelly, Marieke L. Kuijjer, William Barry, Ahmed Rattani, Cassandra C. Garbutt, Haydn Kissick, Katherine Janeway, Antonio Perez-Atayde, Jeffrey Goldsmith, Mark C. Gebhardt, Mohamed S. Arredouani, Greg Cote, Francis Hornicek, Edwin Choy, Zhenfeng Duan…

Current status and perspectives of patient-derived xenograft models in cancer research

Cancers remain a major public health problem worldwide, which still require profound research in both the basic and preclinical fields. Patient-derived xenograft (PDX) models are created when cancerous cells o...

Authors: Yunxin Lai, Xinru Wei, Shouheng Lin, Le Qin, Lin Cheng and Peng Li

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer

Targeted therapy and immunotherapy have revolutionized treatment of various cancers in the past decade. Despite targeted therapy with trastuzumab in Her2-positive gastric cancer patients, survival has been dis...

Authors: Prabhsimranjot Singh, Sudhamshi Toom and Yiwu Huang

Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial

Studies in murine models suggested that platelet desialylation was an important mechanism of thrombocytopenia during sepsis.

Authors: Mei-feng Li, Xiao-li Li, Kai-liang Fan, Ying-yi Yu, Jing Gong, Shu-ying Geng, Ya-feng Liang, Ling Huang, Ji-hua Qiu, Xing-han Tian, Wen-ting Wang, Xiao-lu Zhang, Qing-xia Yu, Yuan-feng Zhang, Peng Lin, Li-na Wang…

Checkpoint inhibitors in hematological malignancies

Inhibitory molecules such as PD-1, CTLA-4, LAG-3, or TIM-3 play a role to keep a balance in immune function. However, many cancers exploit such molecules to escape immune surveillance. Accumulating data suppor...

Authors: Chi Young Ok and Ken H. Young

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

Allogeneic hematopoietic stem cell transplantation (HSCT), the most widely used potentially curable cellular immunotherapeutic approach in the treatment of hematological malignancies, is limited by life-threat...

Authors: Chongsheng Qian, Arnaud Campidelli, Yingying Wang, Huili Cai, Véronique Venard, Hélène Jeulin, Jean Hugues Dalle, Cécile Pochon, Maud D’aveni, Benedicte Bruno, Catherine Paillard, Stéphane Vigouroux, Charlotte Jubert, Patrice Ceballos, Aude Marie-Cardine, Claire Galambrun…

Wnt/beta-catenin pathway: modulating anticancer immune response

Wnt/β-catenin signaling, a highly conserved pathway through evolution, regulates key cellular functions including proliferation, differentiation, migration, genetic stability, apoptosis, and stem cell renewal....

Authors: Sachin Gopalkrishna Pai, Benedito A. Carneiro, Jose Mauricio Mota, Ricardo Costa, Caio Abner Leite, Romualdo Barroso-Sousa, Jason Benjamin Kaplan, Young Kwang Chae and Francis Joseph Giles

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages

Solid tumors residing in tissues and organs leave footprints in circulation through circulating tumor cells (CTCs) and circulating tumor DNAs (ctDNA). Characterization of the ctDNA portraits and comparison wit...

Authors: Meng Yang, Umit Topaloglu, W. Jeffrey Petty, Matthew Pagni, Kristie L. Foley, Stefan C. Grant, Mac Robinson, Rhonda L. Bitting, Alexandra Thomas, Angela T. Alistar, Rodwige J. Desnoyers, Michael Goodman, Carol Albright, Mercedes Porosnicu, Mihaela Vatca, Shadi A. Qasem…

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis

We studied non-driver mutations in 62 subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis upon diagnosis, including 45 subjects with primary myelofibrosis (PMF) and 17 with post-polycythemia

Authors: Bing Li, Robert Peter Gale, Zefeng Xu, Tiejun Qin, Zhen Song, Peihong Zhang, Jie Bai, Lei Zhang, Yue Zhang, Jinqin Liu, Gang Huang and Zhijian Xiao

Emerging therapies for breast cancer

HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall sur...

Authors: Xichun Hu, Wei Huang and Minhao Fan

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which ar...

Authors: Hanxiao Xu, Shengnan Yu, Qian Liu, Xun Yuan, Sridhar Mani, Richard G. Pestell and Kongming Wu

Recent advances in cancer immunotherapy

Authors: Weijing Sun

Immunotherapy in genitourinary malignancies

Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination chemotherapies...

Authors: Kathan Mehta, Keyur Patel and Rahul A. Parikh

Immunotherapy in hematologic malignancies: past, present, and future

The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatme...

Authors: Annie Im and Steven Z. Pavletic

The use of immunotherapy in the treatment of melanoma

Patients with advanced melanoma have a compromised anti-tumor immune response leading to tumor immune tolerance and a tumor microenvironment conducive to disease progression. Immunotherapy that successfully ov...

Authors: Tala Achkar and Ahmad A. Tarhini

The next generation of immunotherapy: keeping lung cancer in check

Lung cancer is the deadliest malignancy with more cancer deaths per year than the next three cancers combined. Despite remarkable advances in targeted therapy, advanced lung cancer patients have not experience...

Authors: Ashwin Somasundaram and Timothy F. Burns

Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress

Gastrointestinal (GI) cancers are a group of highly aggressive malignancies with a huge disease burden worldwide. There is clearly a significant unmet need for new drugs and therapies to further improve the tr...

Authors: Zin W. Myint and Gaurav Goel

A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and tumor recurrence and metastasis are major factors that contribute to the poor outcome of patients with HCC. Long noncoding R...

Authors: Wen Ni, Yuqin Zhang, Zetao Zhan, Feng Ye, Yonghao Liang, Jing Huang, Keli Chen, Longhua Chen and Yi Ding

Emerging therapies for acute myeloid leukemia

Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely ...

Authors: Caner Saygin and Hetty E. Carraway

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma

The B cell maturation process involves multiple steps, which are controlled by relevant pathways and transcription factors. The understanding of the final stages of plasma cell (PC) differentiation could provi...

Authors: Dalia Quwaider, Luis A. Corchete, Irena Misiewicz-Krzeminska, María E. Sarasquete, José J. Pérez, Patryk Krzeminski, Noemí Puig, María Victoria Mateos, Ramón García-Sanz, Ana B. Herrero and Norma C. Gutiérrez